Rhythm Stock Is Up 32%. Is One Drug Enough?

RYTMYTD+8.9%SPYYTD+8.2%XLVYTD+21.1%
Analyze RYTM →

Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?

Rhythm Pharmaceuticals (RYTM) stock gained 32.2% over the past month, compared with a 4.5% loss for the S&P 500. Its largest one-day rise of the past year came on November 4, 2026, the day after the company released its third-quarter report. Buying now means betting on one drug, IMCIVREE, from a company that still loses money. In March, the drug went on sale in the U.S. for its newest use in a rare condition called acquired hypothalamic obesity. So how is that launch going?

Image from Pixabay

Rhythm’s Sales Have Grown Every Quarter For A Year

So far, it is going well. Rhythm’s revenue has risen every quarter for the past year. It reached $92.1 million in the third quarter of 2026, up 79.6% from a year earlier. Management said the U.S. launch in acquired hypothalamic obesity was the main source of growth from the second quarter. By the end of September, Rhythm had received more than 700 forms to start patients on the drug for that condition.

Insurers are also signing on. Management said IMCIVREE policies for the condition covered about 75% of commercially insured lives by the end of the third quarter.

That growth easily outpaces the broader market. Over the past three years, Rhythm’s revenue grew an average of 65.8% a year, compared with 6.5% for the S&P 500.

Can Rhythm Pharmaceuticals Turn Its Sales Into Profit?

Not yet, though the loss is shrinking relative to sales. Rhythm’s operating loss came to 42.6% of revenue in the third quarter of 2026, down from 102.6% in the third quarter of 2025. Over the twelve months to September, the operating loss was still $187 million, about the same as a year before.

Buyers appear to be betting that the loss will close. Rhythm stock trades at 28.7 times its sales over the past twelve months, compared with 3.2 times for the S&P 500. A P/E ratio is not meaningful while the company loses money.

The best case is that sales keep climbing in new markets. IMCIVREE has just gone on sale for the condition in Japan, which management expects to become Rhythm’s second-largest market. Prescriptions there are limited to a two-week supply in the first year, a rule management expects to be lifted in November 2027.

The clearest risk is the money Rhythm has committed. The company agreed to pay LG Chem $350 million over four years in exchange for a lower royalty on its drugs. Management said the present value of those payments will be counted as research and development expense in the fourth quarter. Rhythm finished September with $321 million in cash and short-term investments, before drawing on a new term loan. That $321 million also comes before the first $70 million payment to LG Chem, due in the fourth quarter of 2026. Management expects the cash to fund planned operations for at least 24 months. Cash used in operations was about $3 million in the third quarter and $81.8 million over the twelve months to September. Both figures are well below the operating loss for the same periods.

How Far Has Rhythm Stock Fallen In Market Shocks?

The stock fell as far as 71.0% in the 2022 inflation shock, while the S&P 500 lost 24.0%. During the 2023 regional banking crisis, Rhythm stock dropped 42.0%, against a 6.7% decline for the index. Rhythm has not always suffered steeper declines. Both the stock and the index fell 19.0% in the 2025 tariff shock. In the 2024 market shock tied to the yen, Rhythm slipped 1.8% while the index lost 7.8%.

Rhythm’s worst falls have still been far deeper than the market’s. That matters most for how large a position you are comfortable owning.

For the risk to be worth taking, IMCIVREE sales need to keep rising while the loss keeps shrinking against them. Rhythm is expected to report fourth-quarter results in February 2027, and quarterly revenue and the cash used in operations are the measures to watch. That quarter’s loss will also include the R&D charge for the LG Chem payments.

We have an approach to a stock like this that we are proud of. If yours handles Rhythm better, we would like to hear it.

Found A Better Strategy? We’d Love To Learn.

Ours is the Trefis High Quality (HQ) Portfolio: 30 quality stocks in equal weight. Since its September 2020 launch it has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000. If yours has done better, tell us about it. If not, come take a look.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.